glp-1 receptor agonists mechanism of action glp-1_analogs [TUSOM GLP-1 receptor agonists for individualized
Description
The results showed that all three doses of tirzepatide led to more significant weight loss than 1mg of semaglutide
Understanding weight regain after a nutritional weight loss intervention: systematic review and meta-analysis
Strengths of this study lie in the high validity of the source and the diagnoses
Adults ages 50 to 64 have the highest reported use of GLP-1 medications among age groups
Tirzepatide, the first approved dual GIP/GLP-1 receptor agonist, is a 39-amino acid peptide with an approximately 120-hour half-life supporting once-weekly dosing
Available from: Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis
